

Update

28 October 2011

NEW PATENT APPLICATION

Paranta has filed a new Australian provisional patent application today relating to the use of follistatin in the treatment of respiratory diseases. This new application will further improve the Company's ability to create value in its therapeutic focus area of respiratory diseases.

The Company will also continue its strategy of pursuing opportunities to enhance its broader IP portfolio and expects to file several new patent applications over the coming months.

Ross Barrow
Chief Executive Officer

Paranta Biosystems Limited
A.C.N. 141 027 107